miR-17 Epigenetic Modulation of LKB1 Expression in Tumor Cells Uncovers a New Group of Patients With Poor-Prognosis NSCLC

We read with interest the comments of Dr. Bi et al. regarding our recent article that appeared in the Journal of Thoracic Oncology, and we thank them for the positive comments. As they pointed out, we are aware that H1299 NSCLC cells have a wild-type (WT) KRAS but harbor a NRAS mutation. Nevertheless, as we reported in several published papers, when we introduced KRAS-mutated isoforms to these cells, we noticed a clearly distinct behavior of the...